News

Leadership Update: Geoff Matthews is appointed Chief Scientific Officer

December 14, 2024

Read more

Completion of GLP pivotal toxicology studies with Charles River 

August 08, 2024

Read more

Completion of GMP ACU-0943 batch manufacture with Laurus

June 18, 2024

Read more

Signing with BioCina for drug product/fill and finish.

April 28, 2024

Read more

Collaboration with Centenary Institute on the NIH-supported program to investigate new adjuvants for TB vaccines.

April 22, 2024

Read more

Professor Andrew Wilks elected to the Fellowship of the Australian Academy of Science

June 06, 2023

Read more

Aculeus Therapeutics announces IND-enabling studies to advance lead program ACU-0943 towards clinical trials

October 03, 2022

Read more

Advancing innovation through collaboration: Aculeus and WEHI join forces

August 16, 2022

Read more

Aculeus appoints leading preclinical expert as Strategic Safety and Toxicology advisor

July 11, 2022

Read more

Aculeus and Laurus sign CMC development and manufacturing agreement

February 28, 2022

Read more

Aculeus signs agreements to begin IND-enabling studies for STING program

February 13, 2022

Read more

New Appointment - Head of Immunobiology

November 22, 2021

Read more

Aculeus receives TIA Pipeline Accelerator Voucher to support STING program

July 23, 2021

Read more

Aculeus signs service agreement with WEHI to evaluate ACU-757 in models of COVID-19

June 28, 2021

Read more

Aculeus secures CSIRO kick-start program funding

November 09, 2020

Read more

STING and ENPP1 programs in-licenced from CTxT

June 30, 2020

Read more